| pubmed-article:21272174 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0376298 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C2348534 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0162791 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0027947 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0279516 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:21272174 | lifeskim:mentions | umls-concept:C0238711 | lld:lifeskim |
| pubmed-article:21272174 | pubmed:issue | 1b | lld:pubmed |
| pubmed-article:21272174 | pubmed:dateCreated | 2011-1-28 | lld:pubmed |
| pubmed-article:21272174 | pubmed:abstractText | The use of oral prophylactic antibiotics in patients with neutropenia is controversial and not recommended by this group because of a lack of evidence showing a reduction in mortality and concerns that such practice promotes antimicrobial resistance. Recent evidence has demonstrated non-significant but consistent, improvement in all-cause mortality when fluoroquinolones (FQs) are used as primary prophylaxis. However, the consensus was that this evidence was not strong enough to recommend prophylaxis. The evidence base for FQ prophylaxis is presented alongside current consensus opinion to guide the appropriate and judicious use of these agents. Due consideration is given to patient risk, as it pertains to specific patient populations, as well as the net effect on selective pressure from antibiotics if FQ prophylaxis is routinely used in a target population. The potential costs and consequences of emerging FQ resistance, particularly among Escherichia coli, Clostridium difficile and Gram-positive organisms, are considered. As FQ prophylaxis has been advocated in some chemotherapy protocols, specific regard is given to whether FQ prophylaxis should be used to support these regimens. The group also provides recommendations for monitoring and surveillance of emerging resistance in those centres that have adopted FQ prophylaxis. | lld:pubmed |
| pubmed-article:21272174 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21272174 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21272174 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21272174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21272174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21272174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21272174 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21272174 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21272174 | pubmed:issn | 1445-5994 | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:CainM JMJ | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:SlavinM AMA | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:WeiAA | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:BoothD LDL | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:RitchieD SDS | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:MileshkinLL | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:ThurskyK AKA | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:LingaratnamSS | lld:pubmed |
| pubmed-article:21272174 | pubmed:author | pubmed-author:Australian... | lld:pubmed |
| pubmed-article:21272174 | pubmed:copyrightInfo | © 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians. | lld:pubmed |
| pubmed-article:21272174 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21272174 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:21272174 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21272174 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21272174 | pubmed:pagination | 102-9 | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:meshHeading | pubmed-meshheading:21272174... | lld:pubmed |
| pubmed-article:21272174 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21272174 | pubmed:articleTitle | Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. | lld:pubmed |
| pubmed-article:21272174 | pubmed:affiliation | Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. monica.slavin@petermac.org | lld:pubmed |
| pubmed-article:21272174 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21272174 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21272174 | pubmed:publicationType | Practice Guideline | lld:pubmed |
